早期非小细胞肺癌术后微小残留病灶检测技术与应用进展

doi:10.3760/cma.j.cn371439-20220330-00124

摘要/Abstract

摘要：

手术是早期肺癌的主要治疗手段，但术后仍有复发转移风险。随着分子生物学和检测手段的进步，检测患者术后外周血微小残留病灶（MRD）水平，可以动态监测复发和判断预后。由于MRD检测方法繁多，检测效能参差不齐，缺乏统一标准和前瞻性研究验证，临床应用仍有争议。早期非小细胞肺癌MRD检测的进一步发展有待于技术的进步、检测标准的规范和可信的临床数据。

关键词: 癌，非小细胞肺, 临床研究, 微小残留病灶, 检测技术

Abstract:

Surgery is the mainstay of treatment for early lung cancers， but there is still a risk of recurrence and metastasis after surgery. With the advancement of molecular biology and detection methods， detecting the level of postoperative peripheral blood minimal residual disease （MRD） in patients can dynamically monitor recurrence and determine prognosis. Due to the wide variety of MRD detection methods， uneven detection power， lack of uniform standards and prospective study validation， clinical application is still controversial. The further development of MRD detection for early stage cell lung cancer still needs technical progress， standardized detection criteria and credible clinical data.

Key words: Carcinoma， non-small-cell lung, Clinical study, Minimal residual disease, Detection technology

牛瑞琪, 刘萍萍, 杜瀛瀛. 早期非小细胞肺癌术后微小残留病灶检测技术与应用进展[J]. 国际肿瘤学杂志, 2022, 49(10): 623-626.

Niu Ruiqi, Liu Pingping, Du Yingying. Progress in detection and technology applications of minimal residual disease detection in postoperative early stage non-small cell lung cancers[J]. Journal of International Oncology, 2022, 49(10): 623-626.

参考文献 29

[1]	Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party[J]. Blood, 2018, 131(12): 1275-1291. DOI: 10.1182/blood-2017-09-801498. doi: 10.1182/blood-2017-09-801498 pmid: 29330221
[2]	Benson AB, Venook AP, Al-Hawary MM, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2021, 19(3): 329-359. DOI: 10.6004/jnccn.2021.0012. doi: 10.6004/jnccn.2021.0012
[3]	宁大为, 欧洋, 崔凯, 等. 循环肿瘤细胞的富集方法与临床应用[J]. 国际肿瘤学杂志, 2021, 48(3): 161-171. DOI: 10.3760/cma.j.cn371439-20200629-00033. doi: 10.3760/cma.j.cn371439-20200629-00033
[4]	Gobbini E, Swalduz A, Levra MG, et al. Implementing ctDNA analysis in the clinic: challenges and opportunities in non-small cell lung cancer[J]. Cancers (Basel), 2020, 12(11): 3112. DOI: 10.3390/cancers12113112. doi: 10.3390/cancers12113112
[5]	Poulet G, Massias J, Taly V. Liquid biopsy: general concepts[J]. Acta Cytol, 2019, 63(6): 449-455. DOI: 10.1159/000499337. doi: 10.1159/000499337 pmid: 31091522
[6]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33. DOI: 10.3322/caac.21708. doi: 10.3322/caac.21708
[7]	Shukla N, Hanna N. Neoadjuvant and adjuvant immunotherapy in early-stage non-small cell lung cancer[J]. Lung Cancer (Auckl), 2021, 12: 51-60. DOI: 10.2147/LCTT.S277717. doi: 10.2147/LCTT.S277717
[8]	Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer[J]. Nat Rev Clin Oncol, 2017, 14(9): 531-548. DOI: 10.1038/nrclinonc.2017.14. doi: 10.1038/nrclinonc.2017.14 pmid: 28252003
[9]	Wang YH, Song Z, Hu XY, et al. Circulating tumor DNA analysis for tumor diagnosis[J]. Talanta, 2021, 228: 122220. DOI: 10.1016/j.talanta.2021.122220. doi: 10.1016/j.talanta.2021.122220
[10]	Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution[J]. Nature, 2017, 545(7655): 446-451. DOI: 10.1038/nature22364. doi: 10.1038/nature22364
[11]	Guo N, Lou F, Ma Y, et al. Circulating tumor DNA detection in lung cancer patients before and after surgery[J]. Sci Rep, 2016, 6: 33519. DOI: 10.1038/srep33519. doi: 10.1038/srep33519 pmid: 27641744
[12]	Lin C, Liu X, Zheng B, et al. Liquid biopsy, ctDNA diagnosis through NGS[J]. Life (Basel), 2021, 11(9): 890. DOI: 10.3390/life11090890. doi: 10.3390/life11090890
[13]	Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling[J]. Cancer Discov, 2017, 7(12): 1394-1403. DOI: 10.1158/2159-8290.CD-17-0716. doi: 10.1158/2159-8290.CD-17-0716 pmid: 28899864
[14]	Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA[J]. Sci Transl Med, 2017, 9(403): eaan2415. DOI: 10.1126/scitranslmed.aan2415. doi: 10.1126/scitranslmed.aan2415
[15]	Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC—challenges to implementing ctDNA-based screening and MRD detection[J]. Nat Rev Clin Oncol, 2018, 15(9): 577-586. DOI: 10.1038/s41571-018-0058-3. doi: 10.1038/s41571-018-0058-3
[16]	Chabon JJ, Hamilton EG, Kurtz DM, et al. Integrating genomic features for non-invasive early lung cancer detection[J]. Nature, 2020, 580(7802): 245-251. DOI: 10.1038/s41586-020-2140-0. doi: 10.1038/s41586-020-2140-0
[17]	Machine learning yields lung cancer test[J]. Cancer Discov, 2020, 10(6): 753-754. DOI: 10.1158/2159-8290.CD-NB2020-033. doi: 10.1158/2159-8290.CD-NB2020-033 pmid: 32341019
[18]	Szpechcinski A, Chorostowska-Wynimko J, Kupis W, et al. Quantitative analysis of free-circulating DNA in plasma of patients with resectable NSCLC[J]. Expert Opin Biol Ther, 2012, 12 Suppl 1: S3-S9. DOI: 10.1517/14712598.2012.668519. doi: 10.1517/14712598.2012.668519
[19]	Locke WJ, Guanzon D, Ma C, et al. DNA methylation cancer biomarkers: translation to the clinic[J]. Front Genet, 2019, 10: 1150. DOI: 10.3389/fgene.2019.01150. doi: 10.3389/fgene.2019.01150 pmid: 31803237
[20]	吴一龙, 陆舜, 程颖, 等. 非小细胞肺癌分子残留病灶专家共识[J]. 循证医学, 2021, 21(3): 129-135. DOI: 10.12019/j.issn.1671-5144.2021.03.001. doi: 10.12019/j.issn.1671-5144.2021.03.001
[21]	Liang W, Zhao Y, Huang W, et al. Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA me-thylation sequencing of circulating tumor DNA (ctDNA)[J]. Theranostics, 2019, 9(7): 2056-2070. DOI: 10.7150/thno.28119. doi: 10.7150/thno.28119
[22]	Ooki A, Maleki Z, Tsay JJ, et al. A panel of novel detection and prognostic methylated DNA markers in primary non-small cell lung cancer and serum DNA[J]. Clin Cancer Res, 2017, 23(22): 7141-7152. DOI: 10.1158/1078-0432.CCR-17-1222. doi: 10.1158/1078-0432.CCR-17-1222 pmid: 28855354
[23]	Huang J, Soupir AC, Wang L. Cell-free DNA methylome profiling by MBD-seq with ultra-low input[J]. Epigenetics, 2022, 17(3): 239-252. DOI: 10.1080/15592294.2021.1896984. doi: 10.1080/15592294.2021.1896984
[24]	Kang G, Chen K, Yang F, et al. Monitoring of circulating tumor DNA and its aberrant methylation in the surveillance of surgical lung cancer patients: protocol for a prospective observational study[J]. BMC Cancer, 2019, 19(1): 579. DOI: 10.1186/s12885-019-5751-9. doi: 10.1186/s12885-019-5751-9 pmid: 31195991
[25]	Chen K, Zhao H, Shi Y, et al. Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer (DYNAMIC)[J]. Clin Cancer Res, 2019, 25(23): 7058-7067. DOI: 10.1158/1078-0432.CCR-19-1213. doi: 10.1158/1078-0432.CCR-19-1213 pmid: 31439586
[26]	Ohara S, Suda K, Sakai K, et al. Prognostic implications of pre-operative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study[J]. Transl Lung Cancer Res, 2020, 9(5): 1915-1923. DOI: 10.21037/tlcr-20-505. doi: 10.21037/tlcr-20-505
[27]	Yang M, Topaloglu U, Petty WJ, et al. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages[J]. J Hematol Oncol, 2017, 10(1): 100. DOI: 10.1186/s13045-017-0468-1. doi: 10.1186/s13045-017-0468-1
[28]	Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer[J]. N Engl J Med, 2022, 386(21): 1973-1985. DOI: 10.1056/NEJMoa2202170. doi: 10.1056/NEJMoa2202170
[29]	Provencio M, Calvo V, Romero A, et al. Treatment sequencing in resectable lung cancer: the good and the bad of adjuvant versus neoadjuvant therapy[J]. Am Soc Clin Oncol Educ Book, 2022, 42: 1-18. DOI: 10.1200/EDBK_358995. doi: 10.1200/EDBK_358995 pmid: 35561296